宜明昂科-B 01541.HK 深 沪
交易中 08-07 14:18:29
11.240
+0.240
+2.18%
华盛通- 最 高11.920
- 今 开11.030
- 成交量 295.02万股
- 最 低 10.900
- 昨 收 11.000
- 总市值 45.78亿
- 52周最高 15.660
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 3.210
- 委 比 70.65%
- 总股本 4.07亿
- 历史最高 12.000
- 量 比 2.27
- 振 幅 9.27%
- 历史最低 3.210
- 每 手 200
- 风险率 2.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多【爱建医药】IO 2.0赛道进展喜人，静待下半年产业催化
（来源：爱建证券研究所） 投资要点： 医药板块逆势领涨，跑赢沪深300指数。本周（7/28~8/3）市场冲高回落，反内卷交易明显降温，顺周期回调较多...
08-06 09:21
港股早知道 | 美联储宣布维持基准利率不变！焦炭第五轮提涨于自7月31日零时起开启
焦炭第五轮提涨于自7月31日零时起开启；京东集团：向欧洲消费电子产品零售商CECONOMY发出收购要约；宁德时代中期股东应占溢利同比增加33.02%>>
07-31 08:06
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
Immunocore Holdings plc (Nasdaq: IMCR), a biotech company specializing in immunomodulating medicines for cancer, infectious, and autoimmune diseases, announced it will release its Q2 financial results before US markets open on August 7, 2025. A live teleconference and webcast to discuss the results will follow at 8:00 a.m. EDT (1:00 p.m. BST). Immunocore’s ImmTAX platform focuses on TCR bispecific immunotherapies, with KIMMTRAK approved for treat...
07-31 06:00
港股公告掘金 | 宁德时代中期股东应占溢利305.12亿元 同比增加33.02%
宁德时代中期股东应占溢利305.12亿元 同比增加33.02%;理想汽车-W正式发布家庭六座纯电SUV-理想i8...
07-30 23:08
Immutep Quarterly Activities Report Q4 FY25
Immutep's Q4 FY25 update highlights progress in cancer immunotherapy. TACTI-004 Phase III trial for first-line NSCLC is recruiting at 78 sites across 23 countries. INSIGHT-003 trial shows a 60.8% response rate with efti combo. Head and neck cancer trial achieves 17.6-month median OS. Soft tissue sarcoma trial meets primary endpoint. IMP761 Phase I trial in autoimmune diseases shows promise. The company reports a strong cash position of A$129.69 m...
07-30 12:00
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Immutep Limited will present a poster on its pivotal TACTI-004 Phase III trial at the 2025 World Conference on Lung Cancer in Barcelona. The trial evaluates eftilagimod alfa (efti) combined with pembrolizumab and chemotherapy for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The global trial will enroll approximately 750 patients across 150 sites in over 25 countries. The presentation will highlight the study ...
07-29 12:00
华安证券-医药生物行业周报：医药细分行业持续发散，各细分行业进入逻辑挖掘期-250729
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：研报虎） 主要观点： 本周行情回顾：板块上涨 本周医药生物指数上涨...
07-29 11:06
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Immutep Limited, a late-stage immunotherapy company, announces that three abstracts for clinical trials evaluating its MHC Class II agonist eftilagimod alfa (efti) have been accepted for presentation at the ESMO Congress 2025 in Berlin. The presentations include a Proffered Paper on the EFTISARC-NEO trial in soft tissue sarcoma, a poster on the INSIGHT-003 trial in non-small cell lung cancer (NSCLC), and an ePoster on the pivotal TACTI-004 Phase ...
07-28 12:00
20张图表详解2025Q2公募基金医药持仓背后的变化【周专题&周观点】【总第407期】【国盛医药】
（来源：国医盛视） 一、医药核心观点 当周（7.21-7.25）回顾与周专题： 当周（7.21-7.25）申万医药指数环比+1.90...
07-27 13:55
